Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus ADT in metastatic hormone sensitive prostate cancer
NCT02677896Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Started Mar 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02677896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677896.